دورية أكاديمية
Increased Faecalibacterium abundance is associated with clinical improvement in patients receiving rifaximin treatment.
| العنوان: | Increased Faecalibacterium abundance is associated with clinical improvement in patients receiving rifaximin treatment. |
|---|---|
| المؤلفون: | Ponziani FR; Internal Medicine, Gastroenterology and Hepatology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo Agostino Gemelli 8, 00168 Rome, Italy.; Institute of Special Medical Pathology and Medical Semeiotics, Università Cattolica del Sacro Cuore, 00168 Rome, Italy., Scaldaferri F; Internal Medicine, Gastroenterology and Hepatology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo Agostino Gemelli 8, 00168 Rome, Italy.; Institute of Special Medical Pathology and Medical Semeiotics, Università Cattolica del Sacro Cuore, 00168 Rome, Italy., De Siena M; Internal Medicine, Gastroenterology and Hepatology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo Agostino Gemelli 8, 00168 Rome, Italy., Mangiola F; Internal Medicine, Gastroenterology and Hepatology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo Agostino Gemelli 8, 00168 Rome, Italy., Matteo MV; Internal Medicine, Gastroenterology and Hepatology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo Agostino Gemelli 8, 00168 Rome, Italy., Pecere S; Internal Medicine, Gastroenterology and Hepatology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo Agostino Gemelli 8, 00168 Rome, Italy., Petito V; Internal Medicine, Gastroenterology and Hepatology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo Agostino Gemelli 8, 00168 Rome, Italy., Sterbini FP; Microbiology Unit, Fondazione Policlinico A. Gemelli IRCCS, Largo A. Gemelli 8, 00168 Rome, Italy., Lopetuso LR; Internal Medicine, Gastroenterology and Hepatology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo Agostino Gemelli 8, 00168 Rome, Italy., Masucci L; Microbiology Unit, Fondazione Policlinico A. Gemelli IRCCS, Largo A. Gemelli 8, 00168 Rome, Italy.; Institute of Microbiology, Università Cattolica del Sacro Cuore, Largo F. Vito 1, 00168 Rome, Italy., Cammarota G; Internal Medicine, Gastroenterology and Hepatology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo Agostino Gemelli 8, 00168 Rome, Italy.; Institute of Special Medical Pathology and Medical Semeiotics, Università Cattolica del Sacro Cuore, 00168 Rome, Italy., Sanguinetti M; Microbiology Unit, Fondazione Policlinico A. Gemelli IRCCS, Largo A. Gemelli 8, 00168 Rome, Italy.; Institute of Microbiology, Università Cattolica del Sacro Cuore, Largo F. Vito 1, 00168 Rome, Italy., Gasbarrini A; Internal Medicine, Gastroenterology and Hepatology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo Agostino Gemelli 8, 00168 Rome, Italy.; Institute of Special Medical Pathology and Medical Semeiotics, Università Cattolica del Sacro Cuore, 00168 Rome, Italy. |
| المصدر: | Beneficial microbes [Benef Microbes] 2020 Oct 12; Vol. 11 (6), pp. 519-525. Date of Electronic Publication: 2020 Sep 04. |
| نوع المنشور: | Journal Article; Observational Study |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wageningen Academic Publishers Country of Publication: Netherlands NLM ID: 101507616 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1876-2891 (Electronic) Linking ISSN: 18762883 NLM ISO Abbreviation: Benef Microbes Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Wageningen : Wageningen Academic Publishers |
| مواضيع طبية MeSH: | Diverticular Diseases/*drug therapy , Faecalibacterium/*growth & development , Gastrointestinal Agents/*therapeutic use , Gastrointestinal Microbiome/*drug effects , Inflammatory Bowel Diseases/*drug therapy , Irritable Bowel Syndrome/*drug therapy , Rifaximin/*therapeutic use, Adult ; Bacterial Load/drug effects ; Bacteroidetes/growth & development ; Clostridiales/growth & development ; Diverticular Diseases/microbiology ; Female ; Humans ; Inflammatory Bowel Diseases/microbiology ; Irritable Bowel Syndrome/microbiology ; Male ; Middle Aged |
| مستخلص: | Compositional and functional alterations of the gut microbiota are involved in the pathogenesis of several gastrointestinal diseases. Rifaximin is often used to induce disease remission due to its eubiotic effects on the gut microbiota. To investigate the correlation between changes in the gut microbiota composition and symptoms improvement in patients who present a clinical response to rifaximin treatment. Patients with ulcerative colitis (UC), Crohn's disease (CD), irritable bowel syndrome (IBS) and diverticular disease (DD) undergoing rifaximin treatment for clinical indication were enrolled in the study. Rifaximin was administered at the dose of 1,200 mg/day for 10 days. Faecal samples were collected at baseline and at the end of treatment; clinical improvement was assessed by Mayo score for UC, CD Activity Index (CDAI) for CD, IBS severity scoring system (IBS-SSS) for IBS and global symptomatic score (GSS) for DD. Twenty-five patients were included in the analysis and a clinical improvement was recorded for 10/25 (40%) of them. Microbial alpha diversity showed a slight increase in clinical responders ( P =0.271), while it decreased in patients who did not improved ( P =0.05). A significant post-treatment increase in Faecalibacterium abundance was observed in patients with a positive response (log |
| فهرسة مساهمة: | Keywords: Faecalibacterium; clinical response; eubiotic; gut microbiota; rifaximin |
| المشرفين على المادة: | 0 (Gastrointestinal Agents) L36O5T016N (Rifaximin) |
| تواريخ الأحداث: | Date Created: 20200905 Date Completed: 20210514 Latest Revision: 20210514 |
| رمز التحديث: | 20231215 |
| DOI: | 10.3920/BM2019.0171 |
| PMID: | 32885687 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1876-2891 |
|---|---|
| DOI: | 10.3920/BM2019.0171 |